All themes
Obesity drugs (GLP-1)
47 managers wrote about this in 69 letters. Every passage below is copied verbatim from the letter it came from.
Share of letters mentioning it
- 2024 Q43% of 30
- 2025 Q13% of 40
- 2025 Q23% of 88
- 2025 Q36% of 88
- 2025 Q46% of 129
- 2026 Q14% of 137
- 2026 Q23% of 709
- 2026 Q33% of 863
- 2026 Q45% of 73
Long yoghurt / short crisps For three years the market has treated GLP-1 as a pharmaceutical story with a footnote for the “foods” impact.
Read the letter →- Hennessy Japan FundOct 2026
The rapid uptake of GLP-1 anti-obesity drugs has led to Hennessy Japan Fund (HJPNX/HJPIX) a structural decrease in demand for snack and soft drink products that are high in sugar and calories.
Read the letter → - Somma Investimentos FundsOct 2026
In Europe, the EMA's human medicines committee, the European Medicines Agency, recommended, after its meeting of October 12 to 15, six medicines for authorization: among them (1) Foundayo (orforglipron), from Eli Lilly, an oral GLP-1 for weight control and type 2 diabetes, (2) Rasonque (daraxonrasib), from Revolution Medicines, for metastatic pancreatic cancer and (3) Yuviwel, for pediatric achondroplasia.
Read the letter → - AcatisOct 2026
Novo Nordisk (-13.4%) disappointed at its Capital Markets Day: in particular, the medium-term growth prospects and the outlook following the patent expiration of semaglutide failed to convince investors.
Read the letter → - Baron Fifth Avenue Growth FundSep 2026
Lilly is best known for its GIP/GLP-1 medications for diabetes and obesity.
Read the letter → The stock contributed to performance, driven by stronger-than- expected quarterly revenue and profit and supported by shipments of GLP-1 API validation batches.
Read the letter →- Baron India FundSep 2026
We are e ncourage d that Divi’s has be e n onboarde d by large global pharmaceutical companies as a supplier of complex intermediates and custom-manufactured peptides for oral and injectable GLP-1 therapies.
Read the letter → - Baron International Growth FundSep 2026
Biopharmaceutical spending was strong, GLP-1-related demand is growing, and a broad slate of new products exceeded expectations.
Read the letter → - 1492 Capital Management Vantage Point Quarterly NewsletterSep 2026
It includes large biotechs involved in GLP-1 production for weight loss, for example, and extends to much smaller companies that are creating personalized peptide stacks for tissue repair, immune support, and improved sexual function.
Read the letter → - GreensKeeper Value FundSep 2026
We initially underwrote the investment believing explosive GLP-1 category demand would shield both Novo and Eli Lilly (LLY) from margin pressure.
Read the letter → A prominent growth driver has been the rise of biologics, including GLP-1s. In late 2025 and early 2026, STVN’s share price declined by roughly a third as investors worried that the launch of oral GLP-1 formats would cannibalise sales of injectable formats and reduce demand for the company’s products.
Read the letter →The company delivered another strong quarter, with 13% organic revenue growth driven by continued strength in high-value products across both GLP-1 and non-GLP-1 components.
Read the letter →Investor sentiment improved as the company's shift toward higher-value products continued to gain traction, particularly within biologics and GLP-1 therapies.
Read the letter →Eli Lilly is the leader in GLP-1 diet drugs, while Vertex has broad expertise in developing the most sophisticated technology including gene -editing to address transformative medicines for patients with serious diseases.
Read the letter →We also view the increasing adoption of GLP-1 medications for weight loss as a potential long-term threat to future growth prospects and concluded that McDonald’s no longer warranted inclusion in the Portfolio relative to more attractive long-term investment candidates, such as the two companies profiled above.
Read the letter →Whereas the company pioneered a new class of drugs (the GLP-1), introducing highly efficacious weight loss drugs, investors worry that there is no good follow- on to this blockbuster category.
Read the letter →- Liontrust Global Dividend FundSep 2026
Eli Lilly put to rest any concern that GLP-1 growth is fading, growing revenue 48% year-on-year to $23 billion and raising full year guidance to $85 to $87 billion.
Read the letter → - Malborough US Focus FundSep 2026
The company’s obesity franchise is the largest provider of weight-loss GLP-1 drugs in the world.
Read the letter → - Third Point Offshore Fund, Ltd.Sep 2026
Current themes include GLP-1 losers, cable, P&C insurance, and housing, to name a few.
Read the letter → - Baron Health Care FundSep 2026
Our focus remains on the long-term potential of Lilly’s broader GLP-1 franchise and business rather than solely on Foundayo’s early launch.
Read the letter → Beyond store expansion, Chemist Warehouse is benefiting from the growing adoption of GLP-1 therapies, as customers also purchase complimentary products including protein supplements, beauty products, and haircare products.
Read the letter →It is clear enough that affordability issues and cultural dynamics (such as increased GLP-1 use) are casting long shadows.
Read the letter →Demand is growing quickly, led by China, and salmon is a healthy protein that suits consumers moving to healthier lifestyles, a trend reinforced by GLP-1 drugs.
Read the letter →- AcatisAug 2026
The nutrition business (18%) is recovering: high-pro- tein food supplements to prevent muscle loss are now recommended for patients on weight-loss drugs such as Ozempic.
Read the letter → That focus appears to be paying off: since its January US launch, the Wegovy oral pill had passed 3 million prescriptions by early June (roughly one every five seconds) with more than 80% going to patients new to GLP-1 therapy.
Read the letter →Magnum initially came on to Upslope’s radar as I reviewed out-of-favor consumer staples businesses but sought those with manageable GLP-1 risks due to lower U.S. sales concentration (Magnum is ~25% U.S.).
Read the letter →- Smoak CapitalJun 2026
I believe InBody is a clear GLP-1 beneficiary and management has just begun to discuss the increasing demand they’re seeing along with growing GLP-1 adoption, primarily in the US.
Read the letter → - Baron Fifth Avenue Growth FundJun 2026
Eli Lilly is best known for its GIP/GLP-1 medications for diabetes and obesity.
Read the letter → - 1492 Capital Management Quarterly NewsletterJun 2026
In September 2023, we examined how the rise of GLP-1 weight loss drugs could squeeze restaurant profitability.
Read the letter → - Baron Health Care FundJun 2026
All three major pharmacy benefit managers now cover Lilly's obesity portfolio, including its new daily oral GLP-1, Foundayo.
Read the letter → - Baron International Growth FundJun 2026
We are encouraged that Divi’s has been onboarded by large global innovators and pharmaceutical companies into the oral GLP-1 and GLP-1 injectables value chain as a supplier of complex intermediates and custom manufactured peptides.
Read the letter → The company delivered a strong quarter, with revenue and earnings exceeding expectations, driven by accelerating demand for high-value products and GLP-1 components.
Read the letter →Its growth outlook continues to look favorable, backed by a strong pipeline of products that benefit from global demand for GLP-1 peptides.
Read the letter →More recently, we were one of the first bears that initially pointed out its overall reliance on compounded GLP-1 medications, to its shady prescribing practices for the same drug that led to Novo Nordisk (NVO) terminating their first partnership with the company, and finally, the eventual patent infringement suit against the company by Novo Nordisk in February.
Read the letter →The stock sold off after the launch of oral GLP-1 drugs, which some believe will end the need for injectable formats.
Read the letter →Experts believe an expanding GLP-1 TAM, coupled with varying use cases, will necessitate ongoing need for injectable forms.
Read the letter →Organic revenue increased 15%, and management reinstated its favorable long-term growth outlook as strong demand from biologics and GLP-1 therapies continues to support growth across the portfolio.
Read the letter →Its market- leading Optimum Nutrition protein products have established it as a premier brand in the performance nutrition market, benefiting from an increasing consumer focus on health and wellness, rising protein consumption and growing GLP-1 adoption.
Read the letter →Wegovy pill sales of DKK 2.26 billion were almost double the predicted DKK 1.16 billion, early signs that the new CEO's strategy of pushing volume to offset pricing pressure appears to be showing signs of traction.
Read the letter →Chugai Pharmaceutical declined on the back of weak prescription data for its oral obesity drug even while the company’s reported quarterly results were better than expected.
Read the letter →
Showing the 40 most recent of 69 letters.